Loading market dashboard
Invesco Dorsey Wright Industrials Momentum ETF
PRNFinancial ServicesNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is pleased to announce that the TULSA Procedure™ will be highlighted in four oral presentations at the upcoming American Urological Association's (“AUA”) Annual Meeting in Washington, DC, in the session titled “Prostate Cancer: Localized: Ablative Therapy II” on May 16th from 1:00-3:00 p.m. ET. TULSA Procedure Talks at AUA2026 Ram A.
Profound Medical Corp. (PRN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Profound Medical Corp. (PRN:CA) Q1 2026 Earnings Call Transcript
– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the first quarter ended March 31, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).
PRN hits a new 52-week high as momentum in industrial stocks accelerates, fueled by domestic manufacturing strength.
If you're interested in broad exposure to the Industrials - Broad segment of the equity market, look no further than the Invesco Dorsey Wright Industrials Momentum ETF (PRN), a passively managed exchange traded fund launched on October 12, 2006.
Profound Medical Corp. (TSE: PRN - Get Free Report) Director Dr. Arun Menawat purchased 20,000 shares of Profound Medical stock in a transaction on Friday, March 20th. The shares were purchased at an average cost of C$6.96 per share, with a total value of C$139,200.00. Following the transaction, the director owned 658,660 shares in the company,
All industrial subsectors are significantly overvalued, except transportation. The Invesco Dorsey Wright Industrials Momentum ETF offers superior fundamentals and historical returns versus the sector benchmark XLI. PRN is well-suited for long-term or tactical allocations, though XLI remains preferable for short-term traders due to superior liquidity.
Profound Medical Corp. (PRN:CA) Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer Transcript
